actemra 162 mg s.c.
roche pharmaceuticals (israel) ltd - tocilizumab - solution for injection - tocilizumab 162 mg / 0.9 ml - tocilizumab - - actemra in combination with methotrexate (mtx) is indicated for the treatment of moderate to severe active rheumatoid arthritis (ra) in adult patients who have either responded inadequately to, or who were intolerant to, previous therapy with one or more disease modifying anti rheumatic drugs (dmards) or tumor necrosis factor (tnf) antagonists. in these patients, actemra can be given as monotherapy in case of intolerance to mtx or where continued treatment with mtx is inappropriate. - actemra has been shown to reduce the rate of progression of joint damage as measured by x-ray and to improve physical function when given in combination with methotrexate. - actemra in combination with methotrexate (mtx) in indicated for the treatment of severe, active and progressive rheumatoid arthritis (ra) in adults not previously treated with mtx - actemra (tocilizumab) is indicated for the treatment of giant cell arteritis (gca) in adult patients. - actemra in combination with methotrexate (mtx) is indicated for the treatment of juvenile idiopathic polyarthritis (pjia; rheumatoid factor positive or negative and extended oligoarthritis) in patients 2 years of age and older, who have responded inadequately to previous therapy with mtx. actemra can be given as monotherapy in case of intolerance to mtx or where continued treatment with mtx is inappropriate. - actemra is indicated for the treatment of active systemic juvenile idiopathic arthritis (sjia) in patients 1 year of age and older, who have responded inadequately to previous therapy with nsaids and systemic corticosteroids. actemra can be given as monotherapy (in case of intolerance to mtx or where treatment with mtx is inappropriate) or in combination with mtx.
actemra 20 mg/ml solution for injection/infusion solution for infusion
roche, switzerland - tocilizumab - solution for infusion - 20 mg/ml,
actemra 20 mg/ml solution for injection/infusion solution for infusion
roche, switzerland - tocilizumab - solution for infusion - 20 mg/ml,
actemra 20 mg/ml solution for injection/infusion solution for infusion
roche, switzerland - tocilizumab - solution for infusion - 20 mg/ml,
actemra 162 mg/0.9 ml solution for injection in pre-filled syringe
roche, switzerland - tocilizumab - solution for injection - 180 mg/ml
actemra 200mg/10ml 200 mg/10ml
مستودع ادوية شاوي و رشيدات و مسنات - shawi & rushedat drug store - tocilizumab 200 mg/10ml - 200 mg/10ml
actemra 400mg/20ml 400 mg/20ml
مستودع ادوية شاوي و رشيدات و مسنات - shawi & rushedat drug store - tocilizumab 400 mg/20ml - 400 mg/20ml
actemra 80mg/4ml 80 mg/4ml
مستودع ادوية شاوي و رشيدات و مسنات - shawi & rushedat drug store - tocilizumab 80 mg/4ml - 80 mg/4ml
actemra sc 162mg/0.9ml 162 mg/0.9 ml
مستودع ادوية شاوي و رشيدات و مسنات - shawi & rushedat drug store - tocilizumab 162 mg/0.9 ml - 162 mg/0.9 ml
actemra concentrate for solution for i/v infusion
f. hoffmann-la roche ltd. - tocilizumab - concentrate for solution for i/v infusion - 20mg/ml